Determination of size variants by CE-SDS for approved therapeutic antibodies: Key implications of subclasses and light chain specificities.
CE-SDS
Low molecular weight species
Pharmacopeia method
Quality control
Size variants
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
30 May 2020
30 May 2020
Historique:
received:
29
11
2019
revised:
06
02
2020
accepted:
09
02
2020
pubmed:
1
3
2020
medline:
22
1
2021
entrez:
1
3
2020
Statut:
ppublish
Résumé
In the present work, a generic non-reducing capillary electrophoresis sodium dodecyl sulphate (nrCE-SDS) method was tested for a wide range of 26 FDA and EMA approved monoclonal antibodies (mAbs) and 2 antibody drug conjugates (ADCs) as well as for the NISTmab, in a QC environment (e.g. testing quality requirements for batch manufacturing or batch release). This method allows obtaining rapidly and accurately the amount of size variants in drug products within about 40 min and may be used for batch release and consistency as well as for stability and shelf-life. First, the method repeatability was found to be excellent in terms of relative migration times and relative proportions of fragments (average RSD values of 0.3 and 0.2 %, on relative migration times and relative percentages of fragments, respectively), thanks to the addition of an internal standard. A panel of chimeric, humanized and human mAbs were tested, belonging to different subclasses (heavy chain gamma 1, 2, 2/4 and 4) and light chain types (κ or λ) and produced in different cell lines (CHO, NS0 and SP2/0). For all these biopharmaceutical products, the amount of H2L2 species was comprised between 90.9 % and 97.7 %, except for the two mAbs belonging to the IgG1λ subclass, namely avelumab and belimumab, which were prone to partial reduction during the sample preparation at 70 °C. Based on the CE-SDS results obtained for a diverse panel of therapeutic antibodies investigated in this study, and covering a wide range of structural and physico-chemical properties, a specification on the intact antibody content (H2L2) greater than 90 % can be achieved.
Identifiants
pubmed: 32113118
pii: S0731-7085(19)32910-3
doi: 10.1016/j.jpba.2020.113166
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
Immunoconjugates
0
Immunoglobulin Light Chains
0
Sodium Dodecyl Sulfate
368GB5141J
belimumab
73B0K5S26A
avelumab
KXG2PJ551I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113166Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.